In this article published in Drug Development & Delivery, Pascale Diesel and Lev Gerlovin discuss how as industry works to advance cell and gene therapy development, the debate over new approaches to structuring and financial clinical research continues.
Click here to read the article.
Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...